Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies

Cost: Free

View Offer chevron_right

Details

Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils.

After completing Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies physicians will better be able to:

  • Describe the pathophysiology of ATTR such that it might inform treatment mechanisms
  • Describe available therapies used for treatment of ATTR and explain current literature supporting use of those therapies
  • Design and implement an appropriate therapeutic plan for treatment of ATTR
  • Describe future therapies currently being investigated for the treatment of ATTR

Target Audience: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.